Chlamydia trachomatis vaccine - Emergent BioDefense Operations Lansing

Drug Profile

Chlamydia trachomatis vaccine - Emergent BioDefense Operations Lansing

Alternative Names: TracVax

Latest Information Update: 07 Mar 2006

Price : $50

At a glance

  • Originator Emergent BioDefense Operations Lansing
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Chlamydial infections

Most Recent Events

  • 07 Mar 2006 This vaccine is still in active development
  • 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
  • 11 Feb 2003 Antex has filed an IND with the US FDA for Chlamydial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top